Article

Results reported: Ocular implant safe for AMD in early tests

Rockville, MD-Ocular implants of EntreMed's 2-methoxyestradiol (Panzem) showed no toxicity and effectively inhibited the growth of new blood vessels in preclinical models of age-related macular degeneration (AMD), the company said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
Related Content
Phase 3 study of LUMIFY Preservative Free and LUMIFY eye drops meets primary end point
July 29th 2025

Phase 3 study of LUMIFY Preservative Free and LUMIFY eye drops meets primary end point

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Alcon to showcase next-gen retina tools and clinical data at ASRS annual meeting
July 29th 2025

Alcon to showcase next-gen retina tools and clinical data at ASRS annual meeting

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Alteogen receives positive CHMP opinion for aflibercept biosimilar, EYLUXVI
July 28th 2025

Alteogen receives positive CHMP opinion for aflibercept biosimilar, EYLUXVI

Re-Vana and Boehringer Ingelheim launch $1B collaboration to develop extended-release eye therapies
July 28th 2025

Re-Vana and Boehringer Ingelheim launch $1B collaboration to develop extended-release eye therapies

© 2025 MJH Life Sciences

All rights reserved.